BioCentury
ARTICLE | Company News

CMC Biologics A/S, Serendex deal

February 16, 2015 8:00 AM UTC

CMC granted Serendex exclusive, worldwide rights to develop and commercialize Factor VIIa for pulmonary administration. Serendex said it plans to begin clinical trials to treat diffuse alveolar hemorr...